Alnylam (ALNY) CFO granted options and RSUs, sells 2,206 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ALNYLAM PHARMACEUTICALS, INC. executive vice president and chief financial officer Jeffrey V. Poulton reported a mix of equity awards and stock sales. He received a stock option for 10,480 shares and 4,769 restricted stock units, both granted on March 2, 2026. The RSUs vest in three equal annual installments over three years, and the option vests over four years with 25% after one year and the balance quarterly thereafter, in each case subject to continued service. On the same date, he sold 2,206 shares of common stock in a series of open‑market transactions at weighted average prices in the low‑ to mid‑$320s per share, pursuant to a mandatory sell‑to‑cover provision to satisfy minimum tax withholding. Following these transactions, he directly held 64,273 common shares and indirectly held 57 shares through a managed account.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 2,206 shares ($722,801)
Net Sell
13 txns
Insider
Poulton Jeffrey V.
Role
EVP, Chief Financial Officer
Sold
2,206 shs ($723K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 10,480 | $0.00 | -- |
| Grant/Award | Common Stock | 4,769 | $0.00 | -- |
| Sale | Common Stock | 65 | $323.62 | $21K |
| Sale | Common Stock | 124 | $324.65 | $40K |
| Sale | Common Stock | 356 | $325.63 | $116K |
| Sale | Common Stock | 541 | $326.81 | $177K |
| Sale | Common Stock | 454 | $327.67 | $149K |
| Sale | Common Stock | 138 | $328.71 | $45K |
| Sale | Common Stock | 234 | $329.71 | $77K |
| Sale | Common Stock | 112 | $330.85 | $37K |
| Sale | Common Stock | 129 | $331.93 | $43K |
| Sale | Common Stock | 53 | $332.64 | $18K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 10,480 shares (Direct);
Common Stock — 66,479 shares (Direct);
Common Stock — 57 shares (Indirect, by Managed Account)
Footnotes (1)
- These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
FAQ
What did ALNY CFO Jeffrey Poulton report in his latest Form 4 filing for ALNY?
Jeffrey V. Poulton reported new equity awards and related stock sales. He received 10,480 stock options and 4,769 restricted stock units, and sold 2,206 shares in multiple open-market trades mainly to cover tax withholding obligations tied to the equity awards.
How many ALNY stock options and RSUs were granted to Jeffrey Poulton?
Jeffrey Poulton was granted 10,480 stock options and 4,769 restricted stock units. The RSUs vest in three equal annual installments, while the options vest over four years, both contingent on his continued service with Alnylam Pharmaceuticals during the vesting periods.
Over what schedule do Jeffrey Poulton’s new ALNY equity awards vest?
The restricted stock units vest in three equal parts on each of the first, second, and third anniversaries of the grant. The stock option vests 25% after one year, with the remainder vesting quarterly over the following three years, subject to continuous service.
What prices were reported for Jeffrey Poulton’s ALNY stock sales?
The reported sale prices are weighted averages for trades executed in ranges from about $323.16 to around $332.34 per share. Each footnote notes that individual trades occurred within specific price ranges and that detailed breakdowns are available upon request.